Psoriatic Arthritis News

Patients with psoriatic arthritis in Canada face “substantial burden and unmet need” for improved treatments, as nearly 75% fail to achieve minimal disease activity within 6 months of starting advanced therapy, according to data.

The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.

Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.

In this Healio video, Philip J. Mease, MD, discusses ongoing clinical trials in psoriatic arthritis and data presented at ACR Convergence 2023, as well as upcoming research.

Among patients with rheumatic diseases, the risk for cardiovascular comorbidity is highest during the period immediately before or after initial diagnosis, according to data published in Seminars in Arthritis and Rheumatism.

Izokibep achieved the primary endpoint of ACR50 response in a phase 2b/3 psoriatic arthritis trial, and demonstrated sustained, “deepening” benefit in hidradenitis suppurativa, according to top-line data from its manufacturer.

Screening patients with psoriasis, uveitis or inflammatory bowel disease for spondyloarthritis could improve early diagnosis, but no existing screening tools are generalizable to all who are at risk, according to a scoping review.

In a Healio video exclusive, Gil Y. Melmed, MD, MS, highlights certain therapies that should be avoided or included in the management of patients with extraintestinal manifestations of inflammatory bowel disease.

Fatigue among patients with psoriasis with or without psoriatic arthritis was associated with joint paint, itch and, to a lesser extent, disease severity, according to a study.

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.